semaglutide update Novo Nordisk's shortage officially concludes in the US, spelling major threat for weight loss drug compounders Rybelsus (semaglutide) New Label Update

Discard the medication immediately if you observe any of the following: Particulate matter Color changes such as darkening or browning Crystallization Changes in viscosity These physical changes indicate chemical degradation or contamination

Decreased urine output or difficulty urinating, potentially signaling dehydration or kidney dysfunction Dark-colored or concentrated urine , which typically indicates dehydration, especially following gastrointestinal side effects Painful urination, urgency, or burning sensation , suggesting a possible urinary tract infection that may require antibiotics Blood in the urine (hematuria), which requires prompt evaluation regardless of other symptoms Foamy or frothy urine that persists, potentially indicating proteinuria or kidney disease Dehydration is a particular concern with semaglutide due to its gastrointestinal side effects

Adjust proportionally if your therapeutic dose is lower

PubMed laboratory research record [PMID: 37846993] PubMed record related to this compound for laboratory literature review

The process is identical for both: For Retatrutide (10 mg vials) , add 2 mL of bacteriostatic water to create a concentration of 5 mg per mL

doi: 10.1016/j.biopha.2018.08.088 18 MeierJJ